| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441755 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Combined ridaforolimus and MK-0752 showed activity in HNSCC. However, a high number of adverse events were reported at the MTD, which would require careful management during future clinical development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S.A. Piha-Paul, P.N. Munster, A. Hollebecque, G. Argilés, O. Dajani, J.D. Cheng, R. Wang, A. Swift, A. Tosolini, S. Gupta,